Metagenomi Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.7803 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 29.48M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other...